Multiplex Assay Kit for Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay)

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 94-101 97
EDTA plasma(n=5) 89-96 93
heparin plasma(n=5) 96-104 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-102% 97-104% 83-93% 80-89%
EDTA plasma(n=5) 79-93% 94-102% 88-96% 82-97%
heparin plasma(n=5) 79-91% 87-101% 88-103% 91-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:LRG1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Clin Exp Nephrol Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome PubMed: 26351173
Journal of Proteome Research Targeted proteomics predict a sustained complete-response after transarterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma: a prospective cohort study pubmed:28112944
OncoTargets and Therapy leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter Pubmed:29785123
PROTEOMICS – Clinical Applications Screening and Identification of Pregnancy Zone Protein (PZP) and Leucine‐Rich Alpha‐2‐Glycoprotein (LRG) as Potential Serum Biomarkers for Early‐onset … Pubmed: 30411527
Cancer Management and Research iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemia Pubmed: 31440093
J Clin Med A Three-Protein Panel to Support the Diagnosis of Sepsis in Children Pubmed:35329889
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPB934Ra01 Recombinant Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) Positive Control; Immunogen; SDS-PAGE; WB.
RPB934Ra02 Recombinant Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) Positive Control; Immunogen; SDS-PAGE; WB.
PAB934Ra01 Polyclonal Antibody to Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) WB; IHC; ICC; IP.
PAB934Ra02 Polyclonal Antibody to Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) WB; IHC; ICC; IP.
MAB934Ra22 Monoclonal Antibody to Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) WB; IHC; ICC; IP.
MAB934Ra21 Monoclonal Antibody to Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) WB; IHC; ICC; IP.
SEB934Ra ELISA Kit for Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB934Ra Multiplex Assay Kit for Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.